Zhejiang Jianfeng Group Co., Ltd. Third Quarter Report 2018 Text
Release time:
2020-07-07
公司代码:600668 公司简称:尖峰集团
浙江尖峰集团股份有限公司
2018年第三季度报告正文
一、 重要提示
1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
1.2 公司全体董事出席董事会审议季度报告。
1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人(会计主管人员)吴德富保证季度报告中财务报表的真实、准确、完整。
1.4 本公司第三季度报告未经审计。
二、 公司主要财务数据和股东变化
2.1 主要财务数据
单位:元 币种:人民币
|
|
本报告期末 |
上年度末 |
本报告期末比上年度末增减(%) |
|
总资产 |
4,787,531,214.62 |
4,175,730,846.73 |
14.65 |
|
归属于上市公司股东的净资产 |
3,091,664,703.46 |
2,627,318,888.65 |
17.67
|
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减(%) |
|
经营活动产生的现金流量净额 |
375,343,924.71 |
194,680,761.60 |
92.80 |
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减 (%) |
|
营业收入 |
2,308,365,252.61 |
1,966,202,048.98 |
17.40 |
|
归属于上市公司股东的净利润 |
488,183,289.95 |
291,408,643.10 |
67.53 |
|
归属于上市公司股东的扣除非经常性损益的净利润 |
473,663,318.81 |
277,934,952.23 |
70.42 |
|
加权平均净资产收益率(%) |
17.05 |
11.74 |
增加5.31个百分点 |
|
基本每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
|
稀释每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
非经常性损益项目和金额
单位:元 币种:人民币
|
项目 |
本期金额 (7-9月) |
年初至报告期末金额(1-9月) |
说明 |
|
非流动资产处置损益 |
17,071.47 |
25,797.10 |
|
|
越权审批,或无正式批准文件,或偶发性的税收返还、减免 |
1,344,590.41 |
2,037,104.39 |
|
|
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 |
6,010,443.10 |
15,471,116.32 |
|
|
委托他人投资或管理资产的损益 |
169,552.87 |
1,535,544.14 |
|
|
除上述各项之外的其他营业外收入和支出 |
-24,177.80 |
-680,195.47 |
|
|
少数股东权益影响额(税后) |
-346,385.71 |
-472,835.16 |
|
|
所得税影响额 |
-1,511,067.33 |
-3,396,560.18 |
|
|
合计 |
5,660,027.01 |
14,519,971.14 |
|
2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
单位:股
|
股东总数(户) |
29,258 |
||||||
|
前十名股东持股情况 |
|||||||
|
股东名称 (全称) |
期末持股数量 |
比例(%) |
持有有限售条件股份数量 |
质押或冻结情况 |
股东性质 |
||
|
股份状态 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
16.15 |
0 |
无 |
0 |
国有法人 |
|
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
2.68 |
0 |
无 |
0 |
未知 |
|
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
2.01 |
0 |
无 |
0 |
未知 |
|
|
香港中央结算有限公司 |
4,510,078 |
1.31 |
0 |
无 |
0 |
未知 |
|
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
1.09 |
0 |
无 |
0 |
境内非国有法人 |
|
|
何文康 |
3,439,100 |
1.00 |
0 |
无 |
0 |
境内自然人 |
|
|
王晓红 |
3,121,943 |
0.91 |
0 |
无 |
0 |
境内自然人 |
|
|
骆惠娟 |
2,976,200 |
0.86 |
0 |
无 |
0 |
境内自然人 |
|
|
钟以隆 |
2,650,000 |
0.77 |
0 |
无 |
0 |
境内自然人 |
|
|
徐新华 |
2,544,661 |
0.74 |
0 |
无 |
0 |
境内自然人 |
|
|
前十名无限售条件股东持股情况 |
|||||||
|
股东名称 |
持有无限售条件流通股的数量 |
股份种类及数量 |
|||||
|
种类 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
人民币普通股 |
55,564,103 |
||||
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
人民币普通股 |
9,234,900 |
||||
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
人民币普通股 |
6,922,000 |
||||
|
香港中央结算有限公司 |
4,510,078 |
人民币普通股 |
4,510,078 |
||||
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
人民币普通股 |
3,742,992 |
||||
|
何文康 |
3,439,100 |
人民币普通股 |
3,439,100 |
||||
|
王晓红 |
3,121,943 |
人民币普通股 |
3,121,943 |
||||
|
骆惠娟 |
2,976,200 |
人民币普通股 |
2,976,200 |
||||
|
钟以隆 |
2,650,000 |
人民币普通股 |
2,650,000 |
||||
|
徐新华 |
2,544,661 |
人民币普通股 |
2,544,661 |
||||
|
上述股东关联关系或一致行动的说明 |
本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系,也未知是否属于《上市公司收购管理办法》规定的一致行动人。 |
||||||
|
表决权恢复的优先股股东及持股数量的说明 |
不适用 |
||||||
2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表
三、 重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
|
资产负债表项目 |
期末数(万元) |
期初数(万元) |
变动幅度 |
变动原因 |
|
预付帐款 |
10,245.02 |
4,610.82 |
122.20% |
主要系本报告期子公司预付货款增加所致。 |
|
其他应收款 |
2,095.55 |
1,308.75 |
60.12% |
主要系报告期公司的投资单位已宣告但尚未发放的现金股利增加所致。 |
|
其他流动资产 |
14,482.18 |
1,328.92 |
989.77% |
主要系报告期公司购买的短期银行结构性存款理财产品所致。 |
|
投资性房地产 |
7,964.52 |
2,145.61 |
271.20% |
主要系报告期子公司尖峰国贸在建电商物流园项目部分结转增加所致。 |
|
在建工程 |
2,542.40 |
4,557.67 |
-44.22% |
主要系报告期子公司在建工程项目部分结转相应资产所致。 |
|
商誉 |
7,549.90 |
1,629.86 |
363.22% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
长期待摊费用 |
244.21 |
175.03 |
39.52% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
短期借款 |
14,900.00 |
8,900.00 |
67.42% |
主要系报告期公司及子公司增加银行借款所致。 |
|
应付职工薪酬 |
1,267.86 |
3,627.55 |
-65.05% |
主要系报告期公司及子公司发放上年末计提的年终奖所致。 |
|
其他应付款 |
28,672.64 |
17,432.86 |
64.47% |
主要系报告期子公司计提的市场推广费和其他支出增加及子公司股东会决议宣告但尚未发放的2017年度现金股利增加所致。 |
|
一年内到期的非流动负债 |
0.00 |
27,631.69 |
-100.00% |
主要系报告期公司按期兑付到期的公司债券所致。 |
|
长期借款 |
13,200.00 |
0.00 |
100.00% |
主要系报告期公司新增的长期银行借款及新增合并企业众望制药所致。 |
|
少数股东权益 |
27,469.76 |
19,695.14 |
39.47% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
利润表项目 |
本期数(万元) |
上年同期数(万元) |
变动幅度 |
变动原因 |
|
税金及附加 |
2,156.55 |
1,414.54 |
52.46% |
主要系报告期子公司营业收入增加相应的税金及附加增加所致。 |
|
销售费用 |
34,510.47 |
19,767.16 |
74.58% |
主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整,公司销售费用中相应增加了市场推广费和其他支出。 |
|
投资收益 |
17,306.51 |
10,365.66 |
66.96% |
主要系报告期公司联营投资单位南方尖峰水泥有限公司利润大幅增长,公司权益法核算计入投资收益相应增加所致。 |
|
所得税费用 |
11,927.05 |
7,392.18 |
61.35% |
主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。 |
|
现金流量表项目 |
|
|
|
|
|
经营活动产生的现金流量净额 |
37,534.39 |
19,468.08 |
92.80% |
主要系报告期公司销售收入增长及营业利润大幅增加所致。 |
|
投资活动产生的现金流量净额 |
-24,857.50 |
-21,162.20 |
|
|
|
筹资活动产生的现金流量净额 |
-19,354.57 |
-5,320.98 |
|
主要系报告期公司到期兑付了公司债券本金及利息所致。 |
3.2 重要事项进展情况及其影响和解决方案的分析说明
1.2017年8月3日,本公司九届14次董事会通过了《关于山亚南方股权重组的关联交易的议案》。
本公司控股子公司尖峰水泥持有南方尖峰35%股权,金华南方水泥有限公司(以下简称“金华南方”)持有南方尖峰65%股权;南方尖峰持有杭州山亚南方水泥有限公司(以下简称“山亚南方”)的100%股权。为了压减企业层级、提高运营效率,拟对山亚南方进行股权重组,南方尖峰将所持有的山亚南方100%股权上移,分别转让给尖峰水泥与金华南方两个股东,尖峰水泥与金华南方按所占南方尖峰的股权比例受让山亚南方股权,其中:尖峰水泥拟出资62,099,765元受让山亚南方的35%股权;金华南方拟出资115,328,135元受让山亚南方的65%股权。股权重组完成后,山亚南方的股权层级将上移,重组前后本公司所持该股权的整体权益没有变化。详见2017年8月3日本公司在上海证券交易所网站披露的临2017-019《关于山亚南方股权重组的关联交易公告》。截止报告期末,因支付股权转让款的前提条件尚未达到,该股权重组事项尚未实施。该事项不会影响公司所持的该股权的整体权益。
2.2018年8月3日,公司十届5次董事会通过了《关于子公司尖峰药业对上海北卡增资的议案》本公司控股子公司尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,对上海北卡进行增资,其他股东放弃参与本次增资。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-025《关于子公司尖峰药业对上海北卡增资的公告》。截止报告期末,本次增资事宜已经完成,上海北卡已经完成了工商变更登记手续。上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%。
3. 2018年8月3日,公司十届5次董事会通过了《关于子公司上海北卡收购安徽众望的议案》。本公司控股子公司上海北卡医药技术有限公司出资2062万元,收购安徽众望制药有限公司的全部100%股权,收购完成后安徽众望将成为上海北卡的全资子公司。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-023《关于子公司上海北卡收购安徽众望的公告》。截止报告期末,该股权收购事宜已经完成,安徽众望已经完成工商变更登记手续,成为上海北卡的全资子公司。
4. 2018年8月3日,公司十届5次董事会通过了《关于尖峰药业金西生产基地年产20亿片固体制剂项目的议案》,同意尖峰药业投资建设金西生产基地年产20亿片固体制剂项目。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-024《关于尖峰药业金西生产基地年产20亿片固体制剂项目的公告》。截止报告期末,金西生产基地年产20亿片固体制剂项目的土地指标已经落实,主体工艺设备选型基本完成,工艺设计正在进行中。
5.2017年2月29日,公司九届十次董事会审议通过的《关于子公司对外投资的议案》,本公司控股子公司浙江尖峰药业有限公司拟以增资和股权转让的方式,分期对北京慧宝源生物技术股份有限公司进行投资,其中:第一期出资8,000万元,以每股4元的价格对慧宝源生物增资2,000万股;第二期出资8,600万元,以每股4.30元的价格对慧宝源生物增资2,000万股,另出资3,010万元以每股4.30元的价格受让桂林商源出让的慧宝源生物股权700万股;第三、第四期各对慧宝源生物增资1,400万股,增资价格以届时各方共同认可并聘请的具有证券从业资格的资产评估机构进行评估,以评估结果为基础协商确定。截止报告期末,浙江尖峰药业有限公司已完成了第一期出资,占北京慧宝源生物技术股份有限公司20%的股权。
3.3 报告期内超期未履行完毕的承诺事项
3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
|
公司名称 |
浙江尖峰集团股份有限公司 |
|
法定代表人 |
蒋晓萌 |
|
日期 |
2018年10月30日 |
- 发布时间: 2018-10-31
More information
On December 30, the group company held a special study meeting. Members of the group's party committee and management team concentrated on learning the spirit of the central economic work conference and the Zhejiang provincial party committee economic work conference. From December 16 to 18, the annual Central Economic Work Conference was held in Beijing, which made it clear that in 2021, "we should continue to implement a proactive fiscal policy and a prudent monetary policy, maintain the necessary support for economic recovery, be more accurate and effective in policy operation, do not make sharp turns, and grasp the effectiveness of the policy. It is necessary to make good use of the precious time window, concentrate on promoting reform and innovation, and take high-quality development as the general tone of the 14th five-year Plan. It is proposed to strengthen the national strategic scientific and technological strength, enhance the independent and controllable ability of the industrial chain supply chain, adhere to the strategic basis of expanding domestic demand, and comprehensively promote reform and opening up. On the 25th, the Zhejiang Provincial Party Committee Economic Work Conference was held in Hangzhou to make specific arrangements for the economic development of Zhejiang Province in 2021. At the study meeting, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, together with the leaders attending the meeting, analyzed and studied the key issues raised at the economic work conference of the central and Zhejiang provincial party committees one by one. In his study and discussion, Jiang Xiaomeng stressed that the current neo-coronary pneumonia epidemic is still spreading around the world, the world economy is in a deep recession, the risk of strong stimulus policies in developed countries has spilled over, the global industrial chain supply chain cycle has been blocked, and international trade and investment have shrunk; major strategic achievements have been made in the prevention and control of the domestic epidemic, and the economy has recovered steadily, but there is still greater uncertainty of instability. China has turned to the stage of high-quality development, the economy has been improving for a long time, the development resilience is strong, and the overall social situation is stable. At the same time, the problem of unbalanced and inadequate development in China is still prominent, the reform task of key links in key areas is still arduous, and the innovation ability is not suitable; at present and in the future, China's development is still in an important period of strategic opportunities, but there are new development and changes in opportunities and challenges, we are accelerating the construction of a new development pattern with the domestic cycle as the main body and the domestic and international double cycle promoting each other. The economic work conference of the Central Committee and the Zhejiang provincial Party committee has set the tone and pointed the way for the future development of enterprises. Party organizations at all levels and enterprise management teams should seriously organize and study, deeply understand the spirit of the conference, correctly understand and judge the future policy direction and industry trend, scientifically plan the work of the new year in combination with the actual work of the enterprise, and promote the better development of the enterprise. (this newspaper reporter)
2021
01-04
A few days ago, Tianjin Jianfeng Flanders Company successfully passed the national high-tech enterprise re-identification review work, and once again joined the ranks of high-tech enterprises after the transformation of the enterprise. The original development orientation of Flanders is pharmaceutical excipients, which belongs to the biomedical industry supported by the state. Its products are mainly aimed at major pharmaceutical factories, with clear product standards and strong technical pertinence, so it has been recognized as a national high-tech enterprise for a long time. Starting from 2019, Flanders has embarked on an industrial transformation in the direction of healthy functional foods. The food industry has a variety of products and serves a wide range of people. Enterprises need to come up with products with unique value in order to be accepted and recognized by the market. The difficulty of identifying high-tech enterprises has also increased accordingly. In order to do a good job in the application evaluation of high-tech enterprises, Flanders, in addition to further combing the achievements of previous technological innovation, has also adjusted and established a high-level R & D team on the basis of establishing postdoctoral workstations in cooperation with Shenyang Pharmaceutical University and Tianjin University of traditional Chinese Medicine, and strengthened technological innovation and intellectual property protection in the direction of new industries. For more than a year, Flanders has successfully transformed, produced and put on the market a number of small molecule functional foods and special dietary products such as Huizhi Gold Drink. In order to further accelerate the pace of development in the health food industry, Flanders has successively joined the Tianjin Health Association, Tianjin Food Safety Association and other food industry organizations; and with the strong support of the Tianjin Association for Science and Technology, it began to prepare for the establishment of the Tianjin Medical and Health Society Health Industry Professional Committee. National high-tech enterprises identified once every three years. The person in charge of Flanders said that the company is currently in a critical period of development and transformation. The identification of high-tech enterprises is not only the recognition of the work of Flanders in the past two years by the competent authorities and the industry, but also will provide assistance to the future development of the company. In the future, Flanders will further increase its scientific research efforts, continue to develop and create new products with high-tech content, and make more contributions to public health. (Liu Hairong)
2020
12-22
On the afternoon of December 2, Sang Weiliang, secretary of the Qiandongnan Prefecture Party Committee of Guizhou Province, Wu Ming, deputy director of the Standing Committee of the State People's Congress, Long Zaichong, deputy secretary-general of the State Party Committee, and the main party and government leaders of Huangping County visited Huangping Jianfeng Cement Co., Ltd. to investigate and investigate, and preach the spirit of the Fifth Plenary Session of the 19th Central Committee of the Party. After visiting and understanding the company's production process, Sang Weiliang said happily: "I am very satisfied with the construction of a modern, clean and standardized cement production line in such a short period of time!" At the peak of Huang Ping, Sang Weiliang conveyed and preached the main contents of the spirit of the Fifth Plenary session of the 19th CPC Central Committee. He pointed out that governments at all levels in Qiandongnan Prefecture should thoroughly study and implement the spirit of the Fifth Plenary session of the 19th CPC Central Committee, earnestly implement the decisions and arrangements of the plenary session, focus on the main line of high-quality development, firmly grasp industrial projects, pay close attention to industrial economy, fully promote high-quality economic and social development, and strive to start a new journey of socialist modernization. We should persist in promoting the "four wheels" of new industrialization, we should pay close attention to the industrial economy, accelerate the transformation and upgrading of industrial industries, improve quality and efficiency, and strive to promote high-quality development and achieve stability and long-term development. During the investigation, Hu Hongwei, general manager of Huang Ping Jianfeng, introduced the basic situation of Jianfeng Group and Huang Ping Jianfeng to the state and county leaders, and focused on the equipment and process advantages of the production line, production process, production process, product quality control indicators, as well as various consumption indicators and emission indicators at the leading level in China. He also reported some problems and difficulties encountered after the formal operation of the enterprise. In view of the deficiencies in road traffic construction in Huangping County, Sang Weiliang asked the transportation department to strengthen communication, report and docking, strive for relevant support, do a solid job in the "14th Five-Year Plan" transportation development plan, further improve the road network connection and improve the transportation system, and provide strong support for the development of advantageous enterprises in Huangping Jianfeng and other regions. Sang Weiliang and his party also conducted in-depth research in the production workshop, checked the operation of the production line, and talked with the line staff. At the end of the investigation, he highly affirmed the construction and production work of Huang Ping Jianfeng for more than a year. The development of enterprises must take the road of sustainable development. It is necessary to ensure product quality and take into account the local ecology in order to develop in a long-term and sustainable manner. Sang Weiliang hopes that the Huangping County Government will do its best to ensure service, firmly establish a sense of service, and actively serve the enterprise. Serve, sincerely solve practical difficulties for the enterprise, create a good business environment, and help the enterprise achieve better development; also hope that Huang Ping Jianfeng will continue to play a pioneering role, jointly promote the high-quality economic and social development of Huangping County. (Pan Yi)
2020
12-22
Beirunning won the "13th Five-Year Chinese Medical Science and Technology Iconic Achievement" Award
From December 8 to 11, under the guidance of China Pharmacists Association, China over the counter drug Association and China Medical Education Association, the "2020 national pharmaceutical economic information conference and rice room annual meeting" sponsored by punctuation information (Group) was held in Guangzhou. During the event, the authoritative professional media of Chinese medicine, "Pharmaceutical Economics", released the list of "13th Five-Year China Pharmaceutical Science and Technology Iconic Achievements" and awarded the honorary certificate. The peak pharmaceutical product Berunning (Olopatadine Hydrochloride Eye Drops) is among them. Great changes have taken place in China's pharmaceutical industry during the 13th Five-Year Plan period. Drug review reform, consistency evaluation, volume procurement and other heavy policies in-depth promotion, driving the pharmaceutical industry innovation and upgrading. Chinese pharmaceutical leading enterprises take advantage of the trend, devote themselves to the development of new drugs, actively promote international registration, expand the international market, carry out international mergers and acquisitions, in the world life science stage blooming Chinese style. Lin Jianning, director of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, combed the current operation of the pharmaceutical economy in detail and led the delegates to think deeply about the new changes in the pharmaceutical market in 2021. The industry authoritative media "Pharmaceutical Economic News" sponsored by the Southern Institute of Pharmaceutical Economics released the "13th Five-Year China Pharmaceutical Science and Technology Iconic Achievements" list during the event. The selection of this award aims to explore the scientific and technological achievements of China's pharmaceutical industry during the 13th five-year Plan period from the dimensions of scientific and technological innovation, clinical efficacy, market share and industry influence, so as to help transform pharmaceutical scientific and technological achievements. to help China move from a big pharmaceutical country to a pharmaceutical power. Pinnacle Pharmaceuticals' product, Berunning, is on the list. Berunning is the first eye drops to pass the consistency evaluation in China, and by virtue of its antagonistic histamine H1-receptor, stable mast cell two-way anti-allergy unique efficacy has been widely concerned. Beirunning in the treatment of children with allergic conjunctivitis has good effect, fast curative effect, will not cause significant mast cell degranulation, so the use of more safe, and almost no adverse reactions to the eye tissue, is the current treatment of allergic conjunctivitis an ideal drug. Since its launch in 2019, Berunning has received unanimous recognition and praise from domestic ophthalmologists. (Xu Yuting)
2020
12-22
On December 15, Xing Zhihong, deputy secretary of the Jinhua Municipal CPC Committee and acting mayor, accompanied by Cai Yan, secretary of the Wucheng District CPC Committee, Huang Guojun, and other leaders, visited the company for research, discussed and exchanged views with the company's management team, and put forward hope for the future development of Jianfeng as a leading enterprise in Jinhua City. Jiang Xiaomeng, chairman of the group company, introduced to Xing Zhihong and his party the development strategy, industrial layout, business performance in recent years, scientific and technological innovation, management innovation, as well as the work in charity, poverty alleviation and so on, which was fully affirmed by Xing Zhihong. Xing Zhihong said in the exchange that the peak is Jinhua's landmark enterprise and Jinhua's pride. It is not easy to stick to the industry for many years. Peak has a clear strategic direction and policy, and its good business performance in recent years has fully proved the courage and foresight of the management team. In view of the current situation that the pattern of economic competition at home and abroad is undergoing tremendous changes and the country's increasing requirements for environmental and ecological development, Xing Zhihong hopes that in the future work, Jianfeng will unswervingly follow the path of innovation and development, further increase investment in innovation and research and development, and further promote Green environmental protection production sets an example for Jinhua enterprises. He also hopes that the peak can "lay out the golden industry in the golden area", not only the enterprise itself through technological innovation to achieve high-quality development, but also further lead the upstream and downstream industries, attract potential and competitive enterprises to invest in Jinhua, forming a cluster effect. The municipal party committee and municipal government will also actively study and introduce better support policies to further optimize the business environment, so that enterprises can do a good job in production and operation without distractions, so that Jinhua can form a better industrial ecology. (this newspaper reporter)
2020
12-22